The PRIME-ROSE consortium will be participating in the ESMO Congress 2026 and is pleased to contribute to the scientific program with a poster presentation highlighting the value of international collaboration in precision oncology.

‍

PosterPresentation

827P – Trastuzumab and pertuzumab in HER2 overexpressed / ERBB2 amplified, treatment refractory metastatic colorectal cancer: Merged data from patients treated in the DRUP, FINPROVE, IMPRESS-Norway and ProTarget trials

📅 Sunday, 25 October 2026

This work combines data from four national precision oncology initiatives across Europe, demonstrating how collaboration between molecular screening programs and clinical trial networks can generate valuable evidence for patients with rare molecular alterations.

The presented analysis focuses on patients with HER2-overexpressed or ERBB2-amplified treatment-refractory metastatic colorectal cancer, who received trastuzumab and pertuzumab. By combining datasets from the DRUP (Netherlands), FINPROVE (Finland), IMPRESS-Norway, and ProTarget (Denmark) studies, the collaboration provides important insights into treatment outcomes in this molecularly defined patient population.

Meet the PRIME-ROSE Team at ESMO 2026

ESMO offers an excellent opportunity to connect with researchers, clinicians, patient representatives, industry partners, and policymakers working to advance personalised cancer care across Europe.

The PRIME-ROSE team welcomes discussions with current and potential collaborators interested in:

• Precision oncology implementation
• Molecular tumour boards
• Real-world evidence generation
• Cross-border cancer research     collaboration
• Future European partnership     opportunities

If you will be attending ESMO 2026, we would be delighted to meet and discuss ongoing activities, future collaborations, and opportunities to work together to improve cancer care through personalised approaches.

We look forward to seeing you in Madrid.

‍

‍